Related Experiment Videos
The Association between CHA2DS2-VASc Score and Mortality in Patients with Heart Failure with Reduced Ejection
Orkun Temizer1, Burak Açar1, Çağrı Yayla1
1Türkiye Yüksek Ihtisas Training and Research Hospital, Cardiology Clinic, Ankara, Turkey.
Insights
The CHA2DS2-VASc score effectively predicts 1-year mortality in heart failure patients with reduced ejection fraction. This tool aids in identifying high-risk individuals for improved management and outcomes.
Area of Science:
- Cardiology
- Clinical Medicine
- Medical Research
Background:
- Heart failure (HF) presents significant mortality and morbidity challenges.
- Early identification of high-risk HF patients is crucial for optimizing treatment and reducing adverse events.
- Assessing predictive scores is vital for managing patients with reduced left ventricular ejection fraction (LVEF).
Purpose of the Study:
- To evaluate the CHA2DS2-VASc score's utility in predicting mortality among patients with reduced LVEF.
- To determine if established risk factors correlate with mortality in this specific patient cohort.
- To explore the feasibility of using the CHA2DS2-VASc score for risk stratification in HF patients.
Main Methods:
- A cohort of 106 patients with reduced LVEF was prospectively studied.
- One-year follow-up data was collected for all participants.
- The CHA2DS2-VASc score was calculated for each patient at baseline.
Main Results:
- Mortality was observed in 19.8% of patients within the 1-year follow-up period.
- Baseline functional status, CHA2DS2-VASc score, brain natriuretic peptide, blood urea, and hemoglobin levels were associated with mortality.
- Multivariate analysis identified CHA2DS2-VASc score and functional capacity as independent predictors of 1-year mortality.
Conclusions:
- The CHA2DS2-VASc score is a feasible tool for risk stratification in patients with reduced LVEF.
- This score demonstrates potential for predicting mortality in this population.
- Clinical application of the CHA2DS2-VASc score may enhance patient management strategies.
Background:
Heart failure (HF) is associated with significant mortality and morbidity. Therefore, identifying high-risk patients may optimize treatment for HF patients and reduce adverse events. The aim of this study was to assess the role of the CHA2DS2-VASc score to predict mortality in patients with reduced left ventricular ejection fraction (LVEF).
Methods:
A total of 106 patients with reduced LVEF were enrolled in this study. All patients completed a one-year follow-up, and a CHA2DS2-VASc score was calculated for each patient.
Results:
Twenty-one patients (19.8%) died during the 1-year follow-up. We found that baseline functional status, CHA2DS2-VASc score, brain natriuretic peptide, blood urea and hemoglobin levels were associated with mortality. In the multivariate analysis, CHA2DS2-VASc score and functional capacity were the only predictors of 1-year mortality.
Conclusions:
Use of the CHA2DS2-VASc score appears to be feasible for risk stratification and mortality prediction in patients with reduced LVEF.